Eutropoflavin
Synthetic flavone TrkB agonist, a more potent and stable derivative of tropoflavin (7,8-DHF). Preclinical data only.
Pharmacology
Contents
WHAT IS EUTROPOFLAVIN?
Detailed overview
Eutropoflavin (4'-dimethylamino-7,8-dihydroxyflavone) is a synthetic flavone that acts as a selective small-molecule agonist of tropomyosin receptor kinase B (TrkB), the receptor for BDNF (brain-derived neurotrophic factor), so it mimics BDNF signaling. Compared with tropoflavin (7,8-dihydroxyflavone), it carries a dimethylamino group at the 4' position, which raises its lipophilicity, improves blood-brain-barrier penetration and metabolic stability, making it more potent and longer-lasting than the parent compound. In rodent models it produced neuroprotective, neurogenic and antidepressant-like effects, including hippocampal neurogenesis. There are no human clinical trials: safety and efficacy in humans are unstudied and the compound has never been approved for human use, so it exists only as an experimental research chemical.
Mechanism
Selective TrkB agonist (BDNF mimetic)
Evidence
Preclinical only (no human clinical data)
Legal status
Unapproved research chemical
Receptor profile
- TrkB receptor (BDNF receptor)Strong
- BDNF downstream signaling (ERK / CREB / Akt)Strong
- Hippocampal neurogenesis and synaptic plasticityModerate
Safety
Side effects, stop signs, contraindications
Side effects · 5
- No human safety data: only preclinical (rodent) studies exist; the compound has not been tested in humans in controlled clinical trials
- Theoretical risks of sustained TrkB activation: excessive neurotrophic signaling could in principle carry unfavorable cell-growth effects
- Possible gastrointestinal discomfort or headache at higher doses, typical of flavonoids
- Unknown long-term safety and incomplete toxicity profile in humans
- Unregulated quality and purity: as a research-chemical product, dose and contamination can vary
Contraindications · 3
- Pregnancy and breastfeeding: safety not established, avoid
- Active or prior malignancy: TrkB signaling is overactive in some tumor types, so heightened caution is warranted
- Not an approved medicine; experimental compound, not recommended without clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect
Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease
Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W
O-methylated metabolite of 7,8-dihydroxyflavone activates TrkB receptor and displays antidepressant activity
Liu X, Qi Q, Xiao G, Li J, Luo HR, Ye K
Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET
Bernard-Gauthier V, Boudjemeline M, Rosa-Neto P, Thiel A, Schirrmacher R
FAQ
FAQ
Synthetic flavone TrkB agonist, a more potent and stable derivative of tropoflavin (7,8-DHF). Preclinical data only.
Telegram
Have a question about Eutropoflavin?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.